Home › NDC Lookup › RxCUI directory › RxCUI 485968

Olanzapine 10 MG Injection — RxCUI 485968

RxNorm drug concept · Semantic clinical drug
RxCUI 485968 Semantic clinical drug · SCD ● Current RxNorm concept 24 FDA products 25 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI485968
Official nameOlanzapine 10 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped24
Package NDCs mapped25
Reported Medicaid activity (SDUD)12,021 prescriptions · 33 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Olanzapine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Olanzapine helps bring certain brain chemicals — mainly dopamine and serotonin — back into balance. Depending on what it's prescribed for, it can reduce symptoms of psychosis like...
  • What exactly is olanzapine supposed to do for me?
  • Honestly, yes — weight gain and changes in blood sugar and cholesterol are real and well-documented with olanzapine. Some people gain a significant amount of weight. Blood sugar ca...
  • Will olanzapine make me gain weight or affect my blood sugar?
📖 Read our full Olanzapine guide →

🕸️ Concept Web — How Olanzapine 10 MG Injection Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Olanzapine 10 MG Injection RxCUI 485968

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Olanzapine 61381
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zyprexa 135423
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Olanzapine Injection 1718924
    • Olanzapine Injectable Product 1159556
    • Olanzapine Injection [Zyprexa] 1718927
    • Zyprexa Injectable Product 1186671
    • Injection 1649574
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Olanzapine 10 MG SCDC · 316404
  • Olanzapine Injection SCDF · 1718924
  • Olanzapine Injectable Product SCDG · 1159556

Brand-Name Concepts

  • Olanzapine 10 MG Injection [Zyprexa] SBD · 545353
  • Olanzapine 10 MG [Zyprexa] SBDC · 565155
  • Olanzapine Injection [Zyprexa] SBDF · 1718927
  • Zyprexa Injectable Product SBDG · 1186671
  • Zyprexa BN · 135423

📦 FDA Products & Package NDCs

24 products · 25 package NDCs
25 package NDCs map to RxCUI 485968 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00121-1072-55 1 VIAL in 1 CARTON (0121-1072-55) / 2 mL in 1 VIAL Olanzapine Intramuscular PAI Holdings, LLC dba PAI Pharma 2025-07-25
00143-9199-01 1 VIAL in 1 CARTON (0143-9199-01) / 2 mL in 1 VIAL Olanzapine Hikma Pharmaceuticals USA Inc. 2025-09-18
00517-0955-01 1 VIAL, GLASS in 1 CARTON (0517-0955-01) / 2 mL in 1 VIAL,... Olanzapine American Regent, Inc. 2012-06-27
00781-3159-72 1 VIAL in 1 CARTON (0781-3159-72) / 2 mL in 1 VIAL Olanzapine Sandoz Inc 2011-10-24
00781-9105-72 1 VIAL in 1 CARTON (0781-9105-72) / 2 mL in 1 VIAL Olanzapine Sandoz Inc 2011-10-24
31722-0308-01 1 VIAL in 1 CARTON (31722-308-01) / 2 mL in 1 VIAL Olanzapine Camber Pharmaceuticals, Inc. 2023-03-22
39822-1800-01 1 VIAL in 1 CARTON (39822-1800-1) / 2 mL in 1 VIAL Olanzapine XGen Pharmaceuticals DJB, Inc. 2025-09-02
55150-0308-01 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-308-01) / 1 INJECTIO... OLANZAPINE Eugia US LLC 2020-10-22
55150-0308-10 10 VIAL, SINGLE-DOSE in 1 CARTON (55150-308-10) / 1 INJECTI... OLANZAPINE Eugia US LLC 2020-10-22
61269-0630-30 30 TABLET in 1 BOTTLE (61269-630-30) Zyprexa H2-Pharma LLC 1997-06-23
61269-0631-30 30 TABLET in 1 BOTTLE (61269-631-30) Zyprexa H2-Pharma LLC 1996-10-01
61269-0632-30 30 TABLET in 1 BOTTLE (61269-632-30) Zyprexa H2-Pharma LLC 1996-10-01
61269-0633-30 30 TABLET in 1 BOTTLE (61269-633-30) Zyprexa H2-Pharma LLC 1996-10-01
61269-0634-30 30 TABLET in 1 BOTTLE (61269-634-30) Zyprexa H2-Pharma LLC 2000-01-10
61269-0635-30 30 TABLET in 1 BOTTLE (61269-635-30) Zyprexa H2-Pharma LLC 2001-03-01
61269-0640-20 1 VIAL in 1 CARTON (61269-640-20) / 2 mL in 1 VIAL ZYPREXA Intramuscular H2-Pharma LLC 2004-04-01
61269-0650-35 30 DOSE PACK in 1 CARTON (61269-650-35) / 1 BLISTER PACK in... ZYPREXA Zydis H2-Pharma LLC 2000-06-01
61269-0651-35 30 DOSE PACK in 1 CARTON (61269-651-35) / 1 BLISTER PACK in... ZYPREXA Zydis H2-Pharma LLC 2000-06-01
61269-0652-35 30 DOSE PACK in 1 CARTON (61269-652-35) / 1 BLISTER PACK in... ZYPREXA Zydis H2-Pharma LLC 2001-09-01
61269-0653-35 30 DOSE PACK in 1 CARTON (61269-653-35) / 1 BLISTER PACK in... ZYPREXA Zydis H2-Pharma LLC 2001-09-01
67184-0573-01 1 VIAL in 1 CARTON (67184-0573-1) / 2 mL in 1 VIAL Olanzapine Qilu Pharmaceutical Co., Ltd. 2025-11-11
68462-0952-10 1 VIAL in 1 CARTON (68462-952-10) / 2 mL in 1 VIAL OLANZAPINE GLENMARK PHARMACEUTICALS INC., USA 2026-03-05
72603-0181-01 1 VIAL in 1 CARTON (72603-181-01) / 2 mL in 1 VIAL Olanzapine NorthStar RxLLC 2023-10-16
72843-0576-01 1 VIAL in 1 CARTON (72843-576-01) / 2 mL in 1 VIAL Olanzapine Intramuscular UBI Pharma Inc. 2020-05-08
83854-0003-01 1 VIAL in 1 CARTON (83854-003-01) / 2 mL in 1 VIAL OLANZAPINE Anthea Pharma Private Limited 2026-03-05
Observed labelers: H2-Pharma LLC (11) · Eugia US LLC (2) · Sandoz Inc (2) · American Regent, Inc. (1) · Anthea Pharma Private Limited (1) · Camber Pharmaceuticals, Inc. (1) · +7 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J2359 Inj. olanzapine, 0.5mg 8 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.